TAK-169

N/A

Report date: 2025/05/08 11:40:47

Base Information

Drug NameTAK-169
Drug Alias NameTAK-169MT-0169
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)Biologics > Protein drugs > Toxin
Mechanisms of ActionLymphocyte differentiation antigen CD38 modulators
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsMultiple MyelomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMolecular Templates Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterTakeda Pharmaceutical Co LtdMolecular Templates Inc
Active IndicationsN/A
Inactive IndicationsMultiple MyelomaLeukemia

Other Information

ATC CodeN/A
Related LinksN/A